Estimation of rezdiffra (MGL-3196) by validated RP-HPLC approach in bulk material and pharmaceutical formulation
{{output}}
Introduction: Rezdiffra MGL-3196 is a newly authorized systemic medication for moderate to severe liver fibrosis associated with noncirrhotic nonalcoholic steatohepatitis (NASH). ... ...
